Drugs / HH-006
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07515209 | Dec 2024 → Dec 2025 | chronic hepatitis B virus infection | Huahui Health | Completed | No outcome recorded |
| Phase 1 | NCT05275465 | May → Dec 2022 | hepatitis B virus infection | Huahui Health | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07519330 | May 2026 → Feb 2028 expected | chronic hepatitis B virus infection | Huahui Health | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-05-29 | Huahui Health | Results Phase Ib Data of Huahui Health HH-006 Monoclonal Antibody for Chronic Hepatitis B Virus Infection Presented at EASL 2026 huahuihealth.com ↗
HH-006 demonstrated clear antiviral activity: the mean reduction in HBV DNA change from baseline across all dose groups exceeded that of the placebo group at every assessed time point throughout the study. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-29 | Huahui Health | Phase Ib Data of Huahui Health HH-006 Monoclonal Antibody for Chronic Hepatitis B Virus Infection Presented at EASL 2026 huahuihealth.com ↗ |
| 2022-06-06 | Huahui Health | Huahui Health Initiated First-in-Human Phase I Clinical Trial of Investigational Anti-HBV Antibody HH-006 in Australia huahuihealth.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HH-006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05275465 ↗ |
| Modality | Monoclonal antibody | “hepatitis virus neutralizing monoclonal antibody” NCT05275465 ↗ |
| Route | Subcutaneous | “single ascending doses given as subcutaneous injections” NCT05275465 ↗ |